Improvement of cardiac parameters in patients with acromegaly treated with medical therapies

Pituitary

Volumn 15, Issue 1, 2012, Pages 50-58

  Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Acromegaly; Cardiac function; Cardiomyopathy; Pegvisomant; Somatostatin analogues

Indexed keywords

ANGIOPEPTIN; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE RECEPTOR ANTAGONIST; HORMONE RECEPTOR BLOCKING AGENT; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ACROMEGALY; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; HEART EJECTION FRACTION; HEART FUNCTION; HEART HYPERTROPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HEART VENTRICLE FILLING; HEART VENTRICLE TACHYCARDIA; HUMAN; NEUROSURGERY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; QT PROLONGATION; RADIOTHERAPY; REVIEW; SINUS ARRHYTHMIA; SUPRAVENTRICULAR TACHYCARDIA; SYSTOLIC BLOOD PRESSURE;

ACROMEGALY; CARDIOMYOPATHIES; HUMAN GROWTH HORMONE; HUMANS; SOMATOSTATIN;

EID: 84858154280     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-011-0318-z     Document Type: Review

References (70)

1. Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355:2558-2573
2. Holdaway IM, Rajasoorya C (1999) Epidemiology of acromegaly. Pituitary 2:29-41
3. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769-4775 (Pubitemid 44917305)
4. Schneider HJ, Sievers C, Saller B, Wittchen HU, Stalla GK (2008) High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endocrinol (Oxf) 69:432-435
5. Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102-152 (Pubitemid 38269977)
6. Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674 (Pubitemid 38269875)
7. Colao A, Marzullo P, di Somma C, Lombardi G (2001) Growth hormone and the heart. Clin Endocrinol (Oxf) 54:137-154 (Pubitemid 32194446)
8. Gilbert PL, Siegel RJ, Melmed S, Sherman CT, Fishbein MC (1985) Cardiac morphology in rats with growth hormone-producing tumours. J Mol Cell Cardiol 17:805-811 (Pubitemid 16247465)
9. Ito H, Hiroe M, Hirata Y, Tsujino M, Adachi S, Shichiri M, Koike A, Nogami A, Marumo F (1993) Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 87:1715-1721 (Pubitemid 23133116)
10. Chen DB, Wang L, Wang PH (2000) Insulin-like growth factor I retards apoptotic signaling induced by ethanol in cardiomyocytes. Life Sci 67:1683-1693
11. 2+ handling and enhance cardiac performance. In vitro evaluation in the isolated isovolumic buffer- perfused rat heart. Circ Res 79:227-236
12. Lie JT (1980) Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J 100:41-52
13. van der Klaauw AA, Bax JJ, Bleeker GB, Holman ER, Delgado V, Smit JW, Romijn JA, Pereira AM (2008) Cardiac manifestations of GH deficiency after treatment for acromegaly: a comparison to patients with biochemical remission and controls. Eur J Endocrinol 159:705-712
14. Bogazzi F, Lombardi M, Strata E, Aquaro G, Di Bello V, Cosci C, Sardella C, Talini E, Martino E (2008) High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging. Clin Endocrinol (Oxf) 68: 361-368 (Pubitemid 351257853)
15. Di Bello V, Bogazzi F, Di Cori A, Palagi C, Delle Donne MG, Gavioli S, Talini E, Cosci C, Sardella C, Tonti G, Martino E, Balbarini A, Mariani M (2006) Myocardial systolic strain abnormalities in patients with acromegaly: a prospective color Doppler imaging study. J Endocrinol Invest 29:544-550 (Pubitemid 44164896)
16. Pereira AM, Van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, Smit JW, Romijn JA, Bax JJ (2004) Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 89:71-75 (Pubitemid 38183861)
17. Maffei P, Martini C, Milanesi A, Corfini A, Mioni R, De Carlo E, Menegazzo C, Scanarini M, Vettor R, Federspil G, Sicolo N (2005) Late potentials and ventricular arrhythmias in acromegaly. Int J Cardiol 104:197-203 (Pubitemid 41316990)
18. Fatti LM, Scacchi M, Lavezzi E, Giraldi FP, De Martin M, Toja P, Michailidis G, Stramba-Badiale M, Cavagnini F (2006) Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin Endocrinol (Oxf) 65:626-630 (Pubitemid 44583823)
19. Vitale G, Pivonello R, Auriemma RS, Guerra E, Milone F, Savastano S, Lombardi G, Colao A (2005) Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf) 63:470-476 (Pubitemid 41442344)
20. Kartal I, Oflaz H, Pamukcu B, Meric M, Aral F, Ozbey N, Alagol F (2008) Investigation of early atherosclerotic changes in acromegalic patients. Int J Clin Pract 61:39-44
21. Otsuki M, Kasayama S, Yamamoto H, Saito H, Sumitani S, Kouhara H, Saitoh Y, Ohnishi T, Arita N (2001) Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin Endocrinol (Oxf) 54:791-796 (Pubitemid 34211028)
22. Sakai H, Tsuchiya K, Nakayama C, Iwashima F, Izumiyama H, Doi M, Yoshimoto T, Tsujino M, Yamada S, Hirata Y (2008) Improvement of endothelial dysfunction in acromegaly after transsphenoidal surgery. Endocr J 55:853-859
23. Sze L, Schmid C, Bloch KE, Bernays R, Brandle M (2007) Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol 156:321-329 (Pubitemid 46554500)
24. Davi' MV, Dalle Carbonare L, Giustina A, Ferrari M, Frigo A, Lo Cascio V, Francia G (2008) Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol 159:533-540
25. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr (2001) Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86:4072-4077 (Pubitemid 32848515)
26. Minniti G, Moroni C, Jaffrain-Rea ML, Esposito V, Santoro A, Affricano C, Cantore G, Tamburrano G, Cassone R (2001) Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin Endocrinol (Oxf) 55:307-313 (Pubitemid 32823040)
27. De Marinis L, Bianchi A, Mazziotti G, Mettimano M, Milardi D, Fusco A, Cimino V, Maira G, Pontecorvi A, Giustina A (2008) The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary 11:13-20
28. Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, Cavallo LM, Esposito F, Lombardi G (2008) Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 93:2639-2646 (Pubitemid 352008531)
29. Main G, Borsey DQ, Newton RW (1988) Successful reversal of sleep apnoea syndrome following treatment for acromegaly, confirmed by polygraphic studies. Postgrad Med J 64:945-946 (Pubitemid 19009185)
30. Saeki N, Isono S, Nishino T, Iuchi T, Yamaura A (1999) Sleep-disordered breathing in acromegalics-relation of hormonal levels and quantitative sleep study by means of bedside oximeter. Endocr J 46:585-590 (Pubitemid 29436745)
31. Pelttari L, Polo O, Rauhala E, Vuoriluoto J, Aitasalo K, Hyyppa MT, Kronholm E, Irjala K, Viikari J (1995) Nocturnal breathing abnormalities in acromegaly after adenomectomy. Clin Endocrinol (Oxf) 43:175-182
32. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509-1517
33. Smith WH, Nair RU, Adamson D, Kearney MT, Ball SG, Balmforth AJ (2005) Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts. J Endocrinol 187:379-386 (Pubitemid 43020259)
34. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P (2007) Impact of somatostatin analogs on the heart in acromegaly. A meta-analysis. J Clin Endocrinol Metab 92:1743-1747 (Pubitemid 46997181)
35. Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, Salvatore M, Lombardi G (2003) Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf) 58:169-176 (Pubitemid 36194271)
36. Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G (2000) Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 85:3132-3140
37. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M, Lombardi G (1999) Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 84:17-23 (Pubitemid 29036674)
38. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, Pivonello R, Salvatore M, Lombardi G (2001) Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab 86:1551-1557 (Pubitemid 32374902)
39. Lombardi G, Colao A, Marzullo P, Biondi B, Palmieri E, Fazio S (2002) Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest 25:971-976 (Pubitemid 36113282)
40. Colao A, Ferone D, Cappabianca P, Basso Del, de Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Cali A, de Divitiis E, Lombardi G (1997) Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82:3308-3314 (Pubitemid 27419077)
41. Gunal AI, Isik A, Celiker H, Eren O, Celebi H, Gunal SY, Luleci C (1996) Short term reduction of left ventricular mass in primary hypertrophic cardiomyopathy by octreotide injections. Heart 76:418-421 (Pubitemid 26390798)
42. Lombardi G, Colao A, Ferone D, Marzullo P, Landi ML, Longobardi S, Iervolino E, Cuocolo A, Fazio S, Merola B, Sacca L (1996) Cardiovascular aspects in acromegaly: effects of treatment. Metabolism 45:57-60
43. Ip MS, Tan KC, Peh WC, Lam KS (2001) Effect of Sandostatin®LAR® on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol (Oxf) 55:477-483 (Pubitemid 32955485)
44. Herrmann BL, Wessendorf TE, Ajaj W, Kahlke S, Teschler H, Mann K (2004) Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur J Endocrinol 151:309-315 (Pubitemid 39307317)
45. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716 (Pubitemid 34552506)
46. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ (2002) Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23:623-646 (Pubitemid 35191626)
47. Brue T (2009) ACROSTUDY: status update on 469 patients. Horm Res 71(Suppl 1):34-38
48. Pivonello R, Galderisi M, Auriemma RS, De Martino MC, Galdiero M, Ciccarelli A, D'Errico A, Kourides I, Burman P, Lombardi G, Colao A (2006) Treatment with GH receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab 92:476-482
49. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467-477
50. Cozzi R, Attanasio R, Lodrini S, Lasio G (2004) Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 61:209-215 (Pubitemid 39093116)
51. Bogazzi F, Manetti L, Raffaelli V, Lombardi M, Rossi G, Martino E (2008) Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest 31:119-1123
52. Colao A (2008) The GH/IGF axis and the cardiovascular system: clinical implications. Clin Endocrinol (Oxf) 69:347-358
53. Baldelli R, Ferretti E, Jaffrain-Rea ML, Iacobellis G, Minniti G, Caracciolo B, Moroni C, Cassone R, Gulino A, Tamburrano G (1999) Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab 84:527-532 (Pubitemid 29075679)
54. Baldwin A, Cundy T, Butler J, Timmis AD (1985) Progression of cardiovascular disease in acromegalic patients treated by external pituitary irradiation. Acta Endocrinol (Copenh) 108:26-30 (Pubitemid 15199345)
55. Bogazzi F, Di Bello V, Palagi C, Donne MG, Di Cori A, Gavioli S, Talini E, Cosci C, Sardella C, Brogioni S, Mariani M, Martino E (2005) Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study. Clin Endocrinol (Oxf) 62:590-596 (Pubitemid 40646727)
56. Ciulla MM, Epaminonda P, Paliotti R, Barelli MV, Ronchi C, Cappiello V, Sartorio A, Buonamici V, Magrini F, Beck-Peccoz P, Arosio M (2004) Evaluation of cardiac structure by echoreflectivity analysis in acromegaly: effects of treatment. Eur J Endocrinol 151:179-186 (Pubitemid 39207012)
57. Colao A, Spinelli L, Cuocolo A, Spiezia S, Pivonello R, Di Somma C, Bonaduce D, Salvatore M, Lombardi G (2002) Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab 87:3097-3104 (Pubitemid 34822871)
58. Colao A, Marzullo P, Lombardi G (2002) Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol 146:303-309 (Pubitemid 34257639)
59. Jaffrain-Rea ML, Minniti G, Moroni C, Esposito V, Ferretti E, Santoro A, Infusino T, Tamburrano G, Cantore G, Cassone R (2003) Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly. Eur J Endocrinol 148:193-201 (Pubitemid 36305685)
60. Hayward RP, Emanuel RW, Nabarro JD (1987) Acromegalic heart disease: influence of treatment of the acromegaly on the heart. Q J Med 62:41-58 (Pubitemid 17015915)
61. Hradec J, Kral J, Janota T, Krsek M, Hana V, Marek J, Malik M (1999) Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol 83:1506-1509 (Pubitemid 29228354)
62. Lim MJ, Barkan AL, Buda AJ (1992) Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med 117:719-726
63. Merola B, Cittadini A, Colao A, Ferone D, Fazio S, Sabatini D, Biondi B, Sacca L, Lombardi G (1993) Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 77:790-793 (Pubitemid 23298668)
64. Padayatty SJ, Perrins EJ, Belchetz PE (1996) Octreotide treatment increases exercise capacity in patients with acromegaly. Eur J Endocrinol 134:554-559 (Pubitemid 26188525)
65. Pereira JL, Rodriguez-Puras MJ, Leal-Cerro A, Martinez A, Garcia-Luna PP, Gavilan I, Pumar A, Astorga R (1991) Acromegalic cardiopathy improves after treatment with increasing doses of octreotide. J Endocrinol Invest 14:17-23
66. Thuesen L, Christensen SE, Weeke J, Orskov H, Henningsen P (1989) The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study. Clin Endocrinol (Oxf) 30:619-625 (Pubitemid 19152817)
67. Tokgozoglu SL, Erbas T, Aytemir K, Akalin S, Kes S, Oram E (1994) Effects of octreotide on left ventricular mass in acromegaly. Am J Cardiol 74:1072-1074
68. Vianna CB, Vieira ML, Mady C, Liberman B, Durazzo AE, Knoepfelmacher M, Salgado LR, Ramires JA (2002) Treatment of acromegaly improves myocardial abnormalities. Am Heart J 143:873-876 (Pubitemid 34595347)
69. Colao A, Martino E, Cappabianca P, Cozzi R, Scanarini M, Ghigo E (2006) First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. J Endocrinol Invest 29:1017-1020 (Pubitemid 46344238)
70. Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, Cooper JG, Hald JK, Fougner SL, Bollerslev J (2008) Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 93:2984-2990